Logo
x

Search category

Subscribe Now

All Posts by Date

BMS Presents Two-Year Results of Deucravacitinib in P-III (POETYK PSO) LTE Trial for the Treatment of Plaque Psoriasis at EADV 2022

BMS Presents Two-Year Results of Deucravacitinib in P-III (POETYK PSO) LTE Trial for the Treatment of Plaque Psoriasis at EADV 202...

  • May 12, 2022
Top 20 Medical Device Companies Based on 2021 Revenue

Top 20 Medical Device Companies Based on 2021 Revenue

  • May 12, 2022
Intercept Reports First Patient Dosing of Obeticholic Acid + Bezafibrate in the P-II Study for the Treatment of Primary Biliary Cholangitis

Intercept Reports First Patient Dosing of Obeticholic Acid + Bezafibrate in the P-II Study for the Treatment of Primary Biliary Ch...

  • May 12, 2022
Roche Reports Interim Results of Tiragolumab + Tecentriq (atezolizumab) in P-III (SKYSCRAPER-01) Study for PD-L1-High Metastatic Non-Small Cell Lung Cancer

Roche Reports Interim Results of Tiragolumab + Tecentriq (atezolizumab) in P-III (SKYSCRAPER-01) Study for PD-L1-High Metastatic N...

  • May 12, 2022
Taiho Entered into an Agreement to Acquire Cullinan for CLN-081/TAS6417 to Treat EGFR Exon20 Non-Small Cell Lung Cancer

Taiho Entered into an Agreement to Acquire Cullinan for CLN-081/TAS6417 to Treat EGFR Exon20 Non-Small Cell Lung Cancer

  • May 12, 2022
AbbVie Reports Results of Rinvoq (upadacitinib) P-III (U-ENDURE) Maintenance Study for the Treatment of Crohn's Disease

AbbVie Reports Results of Rinvoq (upadacitinib) P-III (U-ENDURE) Maintenance Study for the Treatment of Crohn's Disease

  • May 12, 2022
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.